Eli Lilly announced that it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, following successful results from two additional late-stage trials [1]. The company had previously indicated it might submit an application as early as this year, but now states that more time is needed to gather and verify manufacturing and quality-control data required by regulators [1].
In the two phase three trials, retatrutide demonstrated significant weight loss and improvements in blood sugar levels among adults with obesity and either Type 2 diabetes or established cardiovascular disease [1]. Specifically, adults with obesity and diabetes lost up to an average of 20.8% of their weight, or nearly 50 pounds, at 80 weeks, while those with severe obesity and established cardiovascular disease lost up to an average of 22.6% of their weight, or 55.8 pounds, at 80 weeks [1]. The drug also meaningfully reduced certain cardiovascular risk factors, according to Lilly [1].
The side effects observed were consistent with previous studies and included diarrhea, nausea, and constipation, which are common across the GLP-1 class of drugs [1]. Retatrutide has now shown positive results in five late-stage trials and is being positioned as the next pillar of Lilly's obesity portfolio, following its injection Zepbound and the newly launched pill, Foundayo [1].
According to Kenneth Custer, president of Lilly Cardiometabolic Health, the company believes it has the necessary data to file for global approval of retatrutide as a treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea [1]. TD Cowen analysts estimated in January that retatrutide could generate sales of $3.8 billion in 2030 [1]. The drug is also seen as critical to Lilly's strategy to maintain its market share majority over Novo Nordisk in the rapidly growing market for weight loss and diabetes drugs, which some analysts estimate could be worth about $100 billion by the 2030s [1].
Retatrutide, referred to as the "triple G" drug, targets GLP-1, GIP, and glucagon, which appears to have more potent effects on appetite and satisfaction with food compared to existing treatments that target only one or two of these hormones [1].
CONCLUSION
Eli Lilly's retatrutide has delivered strong late-stage trial results, prompting the company to plan a regulatory filing in early 2027. The drug's significant weight loss outcomes and potential to address multiple obesity-related conditions position it as a major contender in the expanding weight loss and diabetes market. Market expectations are high, with analysts projecting substantial future sales and strategic importance for Lilly.